Revenue*
13%
to R52 208 million
EBITDA*
22%
to R4 986 million
Operating profit*
60%
to R2 336 million
HEPS
218%
to 334 cents per share
to 512 cents per share
Continuing Core EPS**
215%
to 448 cents per share
* | Excludes the discontinued European shipping business and Consumer Packaged Goods (CPG) in the prior year. Includes Pharmed and the South American shipping business. |
** | Headline earnings are adjusted by items that are not considered to be of a trading nature to arrive at Core EPS. Core EPS is not an IFRS requirement and a reconciliation with Earnings per share (EPS) and Headline Earnings per share (HEPS) is included in the group financial performance section of this report. |
Strong free cash inflow
from continuing operations
excluding CPG of
R900 million
Continuing free cash
conversion of
86%
(F2020: 72%)
Net debt:EBITDA of
1,3x
(F2020: 2,8x)
-well within banking
covenants of 3,25x
Interim cash dividend of
83 cents
per share paid. No final
dividend declared
(F2020: 167 cents)
Concluded disposals of the
shipping businesses for
proceeds of
R4,7 billion
Divisional revenue
Divisional operating profit
Revenue*
(Rm)
* | Excluding businesses held for sale, head office an eliminations. |
Operating profit*
(Rm)
Continuing headline earnings per share (Cents)
Total assets
(Rm)